TRIM28 promotes cervical cancer growth through the mTOR signaling pathway

Li,Fan; Wang,Zhijie; Lu,Gaochuan

doi:10.3892/or.2018.6235

TRIM28 promotes cervical cancer growth through the mTOR signaling pathway

Authors:
- Fan Li
- Zhijie Wang
- Gaochuan Lu
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Shanghai Eighth People's Hospital Affiliated to Jiangsu University, Shanghai 200235, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/or.2018.6235
Pages: 1860-1866

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant expression of tripartite motif-containing protein 28 (TRIM28) has been demonstrated in several human cancers; however, its biological function and related mechanism in cervical cancer remain unclear. In this study, we compared TRIM28 expression between cervical cancer and adjacent normal tissues, and detected significant elevation in TRIM28 expression levels in the cervical cancer tissues. Moreover, TRIM28 overexpression promoted the proliferation, colony formation, and cell cycle progression of cervical cancer cell lines, as well as the growth of xenograft tumors in nude mice, whereas knockdown of TRIM28 had the opposite effects. Evaluation of the potential mechanism demonstrated that TRIM28 promoted cervical cancer cell growth by activating the mammalian target of rapamycin (mTOR) signaling pathway. In support of this finding, TRIM28-induced cell proliferation was abolished by treatment with everolimus, a specific mTOR inhibitor. These results suggest that TRIM28 plays a pivotal role in cervical cancer cell proliferation and might serve as a potential therapeutic target.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ and Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:12–19. 1999. View Article : Google Scholar : PubMed/NCBI
3	Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators, : Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 356:1928–1943. 2007. View Article : Google Scholar : PubMed/NCBI
4	Ozato K, Shin DM, Chang TH and Morse HC III: TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 8:849–860. 2008. View Article : Google Scholar : PubMed/NCBI
5	Gallouet AS, Ferri F, Petit V, Parcelier A, Lewandowski D, Gault N, Barroca V, Le Gras S, Soler E, Grosveld F, et al: Macrophage production and activation are dependent on TRIM33. Oncotarget. 8:5111–5122. 2017. View Article : Google Scholar : PubMed/NCBI
6	Song S, Ge Q, Wang J, Chen H, Tang S, Bi J, Li X, Xie Q and Huang X: TRIM-9 functions in the UNC-6/UNC-40 pathway to regulate ventral guidance. J Genet Genomics. 38:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
7	Raheja R, Liu Y, Hukkelhoven E, Yeh N and Koff A: The ability of TRIM3 to induce growth arrest depends on RING-dependent E3 ligase activity. Biochem J. 458:537–545. 2014. View Article : Google Scholar : PubMed/NCBI
8	Schwamborn JC, Berezikov E and Knoblich JA: The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell. 136:913–925. 2009. View Article : Google Scholar : PubMed/NCBI
9	Yin J, Kim TH, Park N, Shin D, Choi HI, Cho S, Park JB and Kim JH: TRIM71 suppresses tumorigenesis via modulation of Lin28B-let-7-HMGA2 signaling. Oncotarget. 7:79854–79868. 2016. View Article : Google Scholar : PubMed/NCBI
10	Huang Y, Yu Y, Yang Y, Yang M, Zhou L, Huang X and Qin Q: Fish TRIM8 exerts antiviral roles through regulation of the proinflammatory factors and interferon signaling. Fish Shellfish Immunol. 54:435–444. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH and Gao WQ: TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology. 147:1043–1054. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tyybakinoja A, Vilpo J and Knuutila S: High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia. Cytogenet Genome Res. 118:8–12. 2007. View Article : Google Scholar : PubMed/NCBI
13	Chung YL and Wu ML: Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis. J Pathol. 230:377–387. 2013. View Article : Google Scholar : PubMed/NCBI
14	Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, et al: TRIM24 links a non-canonical histone signature to breast cancer. Nature. 468:927–932. 2010. View Article : Google Scholar : PubMed/NCBI
15	Wang S, Kollipara RK, Humphries CG, Ma SH, Hutchinson R, Li R, Siddiqui J, Tomlins SA, Raj GV and Kittler R: The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer. Oncotarget. 7:64921–64931. 2016.PubMed/NCBI
16	Herquel B, Ouararhni K, Khetchoumian K, Ignat M, Teletin M, Mark M, Béchade G, Van Dorsselaer A, Sanglier-Cianférani S, Hamiche A, et al: Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma. Proc Natl Acad Sci USA. 108:pp. 8212–8217. 2011; View Article : Google Scholar : PubMed/NCBI
17	Kim WJ, Wittner BS, Amzallag A, Brannigan BW, Ting DT, Ramaswamy S, Maheswaran S and Haber DA: The WTX tumor suppressor interacts with the transcriptional corepressor TRIM28. J Biol Chem. 290:14381–14390. 2015. View Article : Google Scholar : PubMed/NCBI
18	Pineda CT and Potts PR: Oncogenic MAGEA-TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer. Autophagy. 11:844–846. 2015. View Article : Google Scholar : PubMed/NCBI
19	Yokoe T, Toiyama Y, Okugawa Y, Tanaka K, Ohi M, Inoue Y, Mohri Y, Miki C and Kusunoki M: KAP1 is associated with peritoneal carcinomatosis in gastric cancer. Ann Surg Oncol. 17:821–828. 2010. View Article : Google Scholar : PubMed/NCBI
20	Addison JB, Koontz C, Fugett JH, Creighton CJ, Chen D, Farrugia MK, Padon RR, Voronkova MA, McLaughlin SL, Livengood RH, et al: KAP1 promotes proliferation and metastatic progression of breast cancer cells. Cancer Res. 75:344–355. 2015. View Article : Google Scholar : PubMed/NCBI
21	Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB and Cress WD: Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 287:40106–40118. 2012. View Article : Google Scholar : PubMed/NCBI
22	Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J and Song L: Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res. 17:3089–3099. 2011. View Article : Google Scholar : PubMed/NCBI
23	Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004. View Article : Google Scholar : PubMed/NCBI
24	Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918. 2012. View Article : Google Scholar : PubMed/NCBI
25	Czerwińska P, Shah PK, Tomczak K, Klimczak M, Mazurek S, Sozańska B, Biecek P, Korski K, Filas V, Mackiewicz A, et al: TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development. Oncotarget. 8:863–882. 2017. View Article : Google Scholar : PubMed/NCBI
26	Cammas F, Mark M, Dollé P, Dierich A, Chambon P and Losson R: Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development. Development. 127:2955–2963. 2000.PubMed/NCBI
27	Seki Y, Kurisaki A, Watanabe-Susaki K, Nakajima Y, Nakanishi M, Arai Y, Shiota K, Sugino H and Asashima M: TIF1beta regulates the pluripotency of embryonic stem cells in a phosphorylation-dependent manner. Proc Natl Acad Sci USA. 107:pp. 10926–10931. 2010; View Article : Google Scholar : PubMed/NCBI
28	Wei C, Cheng J, Zhou B, Zhu L, Khan MA, He T, Zhou S, He J, Lu X, Chen H, et al: Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein. Sci Rep. 6:298222016. View Article : Google Scholar : PubMed/NCBI
29	Wang Y, Jiang J, Li Q, Ma H, Xu Z and Gao Y: KAP1 is overexpressed in hepatocellular carcinoma and its clinical significance. Int J Clin Oncol. 21:927–933. 2016. View Article : Google Scholar : PubMed/NCBI
30	Lin LF, Li CF, Wang WJ, Yang WM, Wang DD, Chang WC, Lee WH and Wang JM: Loss of ZBRK1 contributes to the increase of KAP1 and promotes KAP1-mediated metastasis and invasion in cervical cancer. PLoS One. 8:e730332013. View Article : Google Scholar : PubMed/NCBI
31	Pineda CT, Ramanathan S, Fon Tacer K, Weon JL, Potts MB, Ou YH, White MA and Potts PR: Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell. 160:715–728. 2015. View Article : Google Scholar : PubMed/NCBI
32	Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY and Gutkind JS: mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res. 18:2558–2568. 2012. View Article : Google Scholar : PubMed/NCBI
33	Mura M, Hopkins TG, Michael T, Abd-Latip N, Weir J, Aboagye E, Mauri F, Jameson C, Sturge J, Gabra H, et al: LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene. 34:5025–5036. 2015. View Article : Google Scholar : PubMed/NCBI
34	Feng T, Zheng L, Liu F, Xu X, Mao S, Wang X, Liu J, Lu Y, Zhao W, Yu X, et al: Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway. Oncotarget. 7:58381–58395. 2016. View Article : Google Scholar : PubMed/NCBI
35	Biewenga P, Buist MR, Moerland PD, Ver Loren van Themaat E, van Kampen AH, ten Kate FJ and Baas F: Gene expression in early stage cervical cancer. Gynecol Oncol. 108:520–526. 2008. View Article : Google Scholar : PubMed/NCBI